Get the Stockscreener App
6.89
0.00%
0.00
After Hours:
7.08
0.19
+2.76%
Omeros Corporation stock is traded at $6.89, with a volume of 1.08M.
It is up +0.00% in the last 24 hours and up +64.44% over the past month.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$6.89
Open:
$6.89
24h Volume:
1.08M
Relative Volume:
0.34
Market Cap:
$468.90M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
-3.6649
EPS:
-1.88
Net Cash Flow:
$74.30M
1W Performance:
-1.43%
1M Performance:
+64.44%
6M Performance:
+81.55%
1Y Performance:
+61.74%
1-Day Range:
$6.81
$7.0388
1-Week Range:
$6.25
$7.06
52-Week Range:
$2.95
$13.60
Omeros Corporation Stock (OMER) Company Profile
Name
Omeros Corporation
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
6.89 | 449.17M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.19 | 106.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.72 | 68.81B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.74 | 58.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
889.89 | 53.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
377.47 | 36.43B | 4.56B | -176.77M | 225.30M | -1.7177 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corporation Stock (OMER) Latest News
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025 - The Globe and Mail
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? - AOL.com
What candlestick patterns are forming on Omeros CorporationStop Loss & Weekly Top Stock Performers List - newser.com
Ranking Omeros Corporation among high performing stocks via toolsWeekly Trend Summary & Weekly Watchlist for Consistent Profits - newser.com
How strong is Omeros Corporation stock revenue growthWeekly Trade Report & Fast Gaining Stock Reports - newser.com
What technical signals suggest for Omeros Corporation stock2025 Fundamental Recap & Accurate Trade Setup Notifications - newser.com
Will Omeros Corporation stock deliver long term returnsJuly 2025 EndofMonth & Safe Entry Trade Reports - newser.com
Price to sales ratio of Omeros Corporation – HAM:3O8 - TradingView
Omeros Corporation (OMER) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Average basic shares outstanding of Omeros Corporation – HAM:3O8 - TradingView
Omeros (OMER) to Release Quarterly Earnings on Wednesday - MarketBeat
Can Omeros Corporation stock resist market sell offsMarket Activity Summary & Trade Opportunity Analysis - newser.com
Will Omeros Corporation stock recover faster than marketJuly 2025 Rallies & Comprehensive Market Scan Reports - newser.com
Can momentum traders help lift Omeros CorporationJuly 2025 Levels & Verified Chart Pattern Signals - newser.com
Is Omeros Corporation meeting your algorithmic filter criteriaJuly 2025 Analyst Calls & Expert Approved Momentum Ideas - newser.com
Omeros Corporation stock outlook for YEARMarket Performance Report & Reliable Entry Point Alerts - newser.com
Why analysts upgrade Omeros Corporation stockInflation Watch & Short-Term High Return Strategies - fcp.pa.gov.br
38,967 Shares in Omeros Corporation $OMER Bought by Corton Capital Inc. - MarketBeat
Tools to monitor Omeros Corporation recovery probabilityMarket Performance Summary & Low Risk Investment Opportunities - newser.com
Quantitative breakdown of Omeros Corporation recent moveJuly 2025 Patterns & Daily Profit Maximizing Tips - newser.com
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues - GlobeNewswire Inc.
Can OMER stock retain Novo Nordisk driven gains over the long-term? - MSN
What data driven models say about Omeros Corporation’s futureWeekly Trade Recap & Scalable Portfolio Growth Methods - newser.com
Omeros (NASDAQ:OMER) Stock Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder - MSN
Published on: 2025-11-02 12:27:59 - newser.com
Is Omeros Corporation a good long term investmentAnalyst Upgrades & Fast Growing Stocks - earlytimes.in
Published on: 2025-11-04 06:45:17 - earlytimes.in
Published on: 2025-10-31 23:47:38 - newser.com
Omeros Corporation Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):